Geode Capital Management LLC Has $296,000 Stake in Tempest Therapeutics, Inc. (NASDAQ:TPST)

Geode Capital Management LLC raised its position in shares of Tempest Therapeutics, Inc. (NASDAQ:TPST) by 61.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 354,276 shares of the company’s stock after purchasing an additional 134,209 shares during the quarter. Geode Capital Management LLC owned 0.81% of Tempest Therapeutics worth $296,000 at the end of the most recent quarter.

Separately, Virtu Financial LLC acquired a new position in Tempest Therapeutics during the fourth quarter valued at $36,000. 22.52% of the stock is currently owned by institutional investors and hedge funds.

Tempest Therapeutics Trading Up 2.0 %

TPST opened at $6.99 on Friday. The stock has a fifty day moving average price of $8.94 and a 200 day moving average price of $10.94. Tempest Therapeutics, Inc. has a 1 year low of $5.35 and a 1 year high of $49.27. The stock has a market cap of $25.55 million, a price-to-earnings ratio of -4.57 and a beta of -1.78.

Tempest Therapeutics (NASDAQ:TPST) last announced its quarterly earnings results on Thursday, March 27th. The company reported ($4.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.12) by ($0.91). The firm had revenue of $0.49 million during the quarter. As a group, sell-side analysts forecast that Tempest Therapeutics, Inc. will post -1.39 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on TPST. Scotiabank reaffirmed a “sector perform” rating and set a $9.00 target price (up previously from $7.00) on shares of Tempest Therapeutics in a research note on Thursday, April 10th. HC Wainwright reaffirmed a “neutral” rating and set a $16.00 price objective on shares of Tempest Therapeutics in a research report on Thursday, April 10th.

Tempest Therapeutics Company Profile

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.